ARTICLE | Company News
Fox Chase Cancer Center, Horizon Pharma deal
September 14, 2015 7:00 AM UTC
Horizon and Fox Chase partnered to study Horizon’s Actimmune with PD-1/ PD-L1 inhibitors in cancer, including advanced urothelial and renal cell carcinoma. The first study, which is expected to begi...